JL—agree with all your points, but the appeals court is stuck with H-W as is. What AMRN has going for it is a high standard of proof that the CTA could just say was not met by the generics, given the conflicting evidence on what the prior art showed about trig reduction from using pure EPA w/o raising LDL in the severe 500+ cohort. To me some of the best evidence for AMRN is that no one else thought of this for a bunch of years after the prior art cited by Du, even though there was a clear unmet need. Let’s hope we get some appeals judges with some common sense and backbone.
News 
Market Data 
Discover 
